A5049971021- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Eosinophilic Disorders and Syndromes
- Acute Lymphoblastic Leukemia research
- Acute Myeloid Leukemia Research
- Lymphoma Diagnosis and Treatment
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Click Chemistry and Applications
- HER2/EGFR in Cancer Research
- Lung Cancer Treatments and Mutations
- Hematopoietic Stem Cell Transplantation
- Fungal Plant Pathogen Control
- Immune Cell Function and Interaction
- Quinazolinone synthesis and applications
- Mast cells and histamine
- Gastrointestinal Tumor Research and Treatment
- CAR-T cell therapy research
- Monoclonal and Polyclonal Antibodies Research
- T-cell and B-cell Immunology
- HIV/AIDS drug development and treatment
- Bone health and treatments
- Protein Tyrosine Phosphatases
- PI3K/AKT/mTOR signaling in cancer
- RNA Research and Splicing
- Immune cells in cancer
South Australian Health and Medical Research Institute
2016-2025
South Australia Pathology
2015-2024
The University of Adelaide
2015-2024
Royal Adelaide Hospital
2015-2024
Charité - Universitätsmedizin Berlin
2006-2024
Institute of Hematology & Blood Diseases Hospital
2024
Cancer Research Institute
2024
Chinese Academy of Medical Sciences & Peking Union Medical College
2024
Jena University Hospital
2011-2024
Australasian Leukaemia and Lymphoma Group
2014-2024
Imatinib, a selective inhibitor of the BCR-ABL tyrosine kinase, produces high response rates in patients with chronic-phase chronic myeloid leukemia (CML) who have had no to interferon alfa. We compared efficacy imatinib that alfa combined low-dose cytarabine newly diagnosed CML.
The cause of chronic myeloid leukemia (CML) is a constitutively active BCR-ABL tyrosine kinase. Imatinib inhibits this kinase, and in short-term study was superior to interferon alfa plus cytarabine for newly diagnosed CML the phase. For 5 years, we followed patients with who received imatinib as initial therapy.We randomly assigned 553 receive then evaluated them overall event-free survival; progression accelerated-phase or blast crisis; hematologic, cytogenetic, molecular responses;...
Nilotinib has been shown to be a more potent inhibitor of BCR-ABL than imatinib. We evaluated the efficacy and safety nilotinib, as compared with imatinib, in patients newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (CML) phase.In this phase 3, randomized, open-label, multicenter study, we assigned 846 chronic-phase CML 1:1:1 ratio receive nilotinib (at dose either 300 mg or 400 twice daily) imatinib once daily). The primary end point was rate major molecular...
Philadelphia chromosome–like acute lymphoblastic leukemia (Ph-like ALL) is characterized by a gene-expression profile similar to that of BCR–ABL1–positive ALL, alterations lymphoid transcription factor genes, and poor outcome. The frequency spectrum genetic in Ph-like ALL its responsiveness tyrosine kinase inhibition are undefined, especially adolescents adults.
In a randomized trial, 1106 patients with chronic myeloid leukemia (CML) in phase were assigned to imatinib or interferon alfa plus cytarabine as initial therapy. We measured levels of BCR-ABL transcripts the blood all this trial who had complete cytogenetic remission.Levels by quantitative real-time polymerase-chain-reaction assay. Results expressed relative median level 30 untreated CML phase.In remission, after 12 months treatment fallen at least 3 log 57 percent those group and 24 given...
Imatinib, a selective BCR-ABL1 kinase inhibitor, improved the prognosis for patients with chronic myeloid leukemia (CML). We conducted efficacy and safety analyses on basis of more than 10 years follow-up in CML who were treated imatinib as initial therapy.In this open-label, multicenter trial crossover design, we randomly assigned newly diagnosed phase to receive either or interferon alfa plus cytarabine. Long-term included overall survival, response treatment, serious adverse events.The...
Ponatinib is a potent oral tyrosine kinase inhibitor of unmutated and mutated BCR-ABL, including BCR-ABL with the inhibitor–refractory threonine-to-isoleucine mutation at position 315 (T315I). We conducted phase 2 trial ponatinib in patients chronic myeloid leukemia (CML) or Philadelphia chromosome–positive acute lymphoblastic (Ph-positive ALL).
In the phase 3 Evaluating Nilotinib Efficacy and Safety in Clinical Trials-Newly Diagnosed Patients (ENESTnd) study, nilotinib resulted earlier higher response rates a lower risk of progression to accelerated phase/blast crisis (AP/BC) than imatinib patients with newly diagnosed chronic myeloid leukemia (CML-CP). Here, patients' long-term outcomes ENESTnd are evaluated after minimum follow-up 5 years. By years, more half all each arm (300 mg twice daily, 54%; 400 52%) achieved molecular 4.5...
Dasatinib is a BCR-ABL inhibitor, 325-fold more potent than imatinib against unmutated in vitro. Phase II studies have demonstrated efficacy and safety with dasatinib 70 mg twice daily chronic-phase (CP) chronic myelogenous leukemia (CML) after treatment failure. In phase I, responses occurred once-daily administration despite only intermittent inhibition. Once-daily resulted less toxicity, suggesting that toxicity results from continuous inhibition of unintended targets. Here, dose-...